The Cannavist Issue 6 B2C | Page 26

New study GIVES HOPE TO FIBROMYALGIA SUFFERERS CBD and medical cannabis have been touted as potential f ibromyalgia treatments. A recent Italian study demonstrated that cannabinoids could be an ally in the f ight against pain, sleep problems and anxiety. Words by Caroline Barry Cannabis can improve the effectiveness of standard pain treatments in patients with f ibromyalgia, according to a new Italian study. Just under half of the participants felt able to reduce their standard pain relief regimen or even quit it completely after being treated with medical cannabis. One third of the participants reported improvements in sleep and fi bromyalgia symptoms and half reported a reduction in depression and anxiety. The researchers concluded: “Medical cannabis offers a possible clinical advantage in FM [fi bromyalgia] patients, especially in those with sleep dysfunctions. “The retention rate and changes in concomitant analgesic therapy refl ect MCT effi cacy of the improved quality of life of patients.” Fibromyalgia is a long-term condition that causes pain all over the body. The NHS estimates that 1 in 20 people suffer from the condition and women are seven times more likely than men to develop it. In the study published in the journal Clinical and Experimental Rheumatology, 102 patients were given access to Bedrocan, a cannabis oil that has a THC content of 22% and less than 1% CBD, and 26 Bediol oil, which contains 6.3% THC and 8% CBD. Participants were encouraged to take the oil for six months while decreasing or quitting their existing medication if they felt they could. Prior studies have shown that medical cannabis is an effective alternative medication, but this is the fi rst study to suggest that it is benefi cial to take alongside pain medication. The exact cause of fi bromyalgia is unknown, but it is thought to be linked to abnormal levels of certain chemicals in the brain and changes to the way that the central nervous system transmits pain messages around the body. There is currently no cure, with sufferers reduced to taking over-the-counter pain medication to treat symptoms such as joint pain, fatigue, anxiety, depression and sleep disturbances. Some sufferers also report tension headaches and irritable bowel syndrome. A Fibromyalgia UK spokesperson said in a statement that the UK has a long way to go in terms of access, but that the new study is cause for celebration. “We would have to echo the sentiments of Health Secretary Matt Hancock that this is a "tremendous step forward. “However, due to the lack of research in respect of chronic pain and cannabis and specifi cally fi bromyalgia we will continue to have people being pushed to break the law in order to access a treatment that can potentially help them.”